TODAY, WE ARE GOING TO SOLVE A BIG PROBLEM.....

TEAM LARKS

Chien Yi Hsin, Lavendar Tian, Rei Wei, Angela Wang, Tan Kay Wen

FEB, 2020

The Problem: 400 million men are looking for proper, private and satisfactory help on Impotency or Erectile Dysfunction (ED).



1 in 5 men suffer from ED



Concerns for ED patients



Embarrassment doing test in public hospital



Privacy confidential concern for test result



Inconvenience & Inconclusive

70% patients are not satisfied with diagnosis and treatment process

* source: Internal meta-analysis of global ED prevalence studies

Problem



Tumeter is a home-based erectile dysfunction device providing specific nocturnal penile tumescence (NPT) test.







- Skin-friendly material
- Non-invasive experience
- Easy to use

- Real-time monitor for every erection;
- Profound analysis data e.g. strength, blood flow
- Data interaction with clinics

Awards & Recognition



Ranked among the top 10% of all applicants for **Y-combinator**'s s2019 (marked promising and invited to apply for the w2020 cohort)





Patent Information

Pub. No.: WO/2019/239277 International Application No.: PCT/IB2019/054801 Publication Date: 19.12.2019 International Filing Date: 10.06.2019

IPC: G16H 50/20 (2018.01) (?)

* https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019239277&_cid=P21-K60JLW-47116-1



Problem Solution Target Market Si

Strategy Financial

Competition: Home-based, high accuracy and affordable price set Tumeter out from similar products currently in the market.

	Sanwe	Rigiscan	Hiensor	Tumeter
Accuracy	Very High 95%	High 88%	Medium Unknown	High 85%+
Diagnostic principle	NPT + PSG	NPT	NPT	NPT+EOG+EEG
Convenience	Low Hospital-based	Low Hospital-based	High Home-based	High Home-based
Business model	B2B Product Selling	B2B Product Selling	B2C Product Selling	B2B Product renting
Price	High 10,000SGD	High 200SGD/Once	TBD	Medium 60 USD/Once
Al adopted	No	No	No	In progress




Target Market Problem Solution

Strategy

Financial

The Solution: Tumeter is a home-based erectile dysfunction device providing diagnostic parameters by applying multiple tests.

Nocturnal Penile Tumescence (NPT) Test




- ✓ Stay in clinic ward
- ✓ Wait for 2-3 days for results
- ✓ Expensive in terms of total expense

Electrooculography (EOG) & Electroencephalography (EEG) Test



- ✓ Monitoring during sleep
- ✓ Patient to wear eye mask
- ✓ Detecting parameters related to sleep activities





Target Market (1/2): While ED is a global issue and Tumeter is applicable across geographies, the target market for the first phase is Taiwan.





Problem





	US	Mainland China	Taiwan
Sex Ratio (Males)	49.50%	51.30%	49.70%
Population ratio by age group			
25-54	39.10%	46.30%	45.20%
55-64	12.80%	12.20%	14.90%
65+	16.60%	12.00%	15.80%
Complexity of medical market entrance	Medium	High	Low
requirement	FDA Approval (510K)	CFDA Approval (Additional local test)	TFDA Approval
Lead time	200 days	400 days	200 days
Requirement of set-up resources	High	Medium	Low

^{*} source: Worldometer



Target Market (2/2): Taiwan has multiple advantages for start-up entry.



Lean Startup:

- ✓ Small capital required
- Open multiple business models



Accessibility to patients

- √ 19 medical centers with close proximity
- 82%+ of NHI reimbursement funding
- √ 70% of total patients



Strategic Location

- ✓ Close to Mainland China
- Beneficial for business expansion



Contract Manufacture Partner

- More than 781 medical device manufacturers.
- Capability for medical device production at low cost.

Addressable Market Segment: Taiwan provides a variety of medical segments

for validating commercialization strategies.











	Medical Center	Regional Hospital	Clinics	Medical Laboratories	Medical Device Retailer
Pain point	High admission feeLack of data base for ED	High admission fee	Current device is unaffordable	No hospital bed and ward for NPT test	Low guarantee for privacy, affordable cost and convenience
Service focus	Accurate diagnosis and high-quality medical treatment Advanced research	High-quality medical treatment at low cost	Mature and affordable technology & device for daily medical service	Prompt & Accurate 3rd- party diagnosis test	Home-based diagnosis & monitoring solution
Quantity	19	77	11,580	210	34,593
Market Size	US\$ 16B – 20B	US\$ 1.2B -1.6B	US\$ 4.5B – 4.55B	US\$ 500M - 600M	US\$ 1.9B - 2.0B



8

Solution vs Market Segment Matrix: A deep dive on the pain points and benefits of Tumeter® to segments provides direction insights.

Customer		Patient (E	For Doctor (Sales Target)			
Feature Market	Time Saving	Affordability	Long-term Follow-up	Easy to Use	Diagnosis Accuracy Rate	Medical Resource Saving
Medical Center						
Regional Hospital						
Clinics						
Medical Laboratories						
Medical Device Retailer						



Solution

Target Customer: Potential customers are middle-class men who are suffering ED and aging between 40 and 64.

		Male Patients' Age (years old)							
		30 - 39	40 - 49	50 - 64					
me	> middle class	 Population: 0.53M Estimated ED pt': 132,500 Budget: High Incentive: High Prefer Channel: Medical Center Convenience required: High 	 Population: 0.64M Estimated ED pt': 160,000 Budget: High Incentive: High Prefer Channel: Medical Center Convenience required: High 	 Population: 1.03M Estimated ED pt': 266,770 Budget: High Incentive: High Prefer Channel: Medical Center Convenience required: High 					
Income	< middle class	 Population: 1.25M Estimated ED pt':312,500 Budget: Medium Incentive: High Prefer Channel: Regional Hospital Convenience required: Medium 	 Population: 1.20M Estimated ED pt': 300,000 Budget: Medium Incentive: Medium Prefer Channel: Regional Hospital Convenience required: Medium 	 Population: 1.55M Estimated ED pt': 401,450 Budget: Low Incentive: Low Prefer Channel: Clinics Convenience required: Low 					

Stage 1

Middle class men with age between 40 – 64 who mainly go to medical center for ED treatment is our target customers.

Stage 2

Through well-built channels, to expand customers into 2nd tier.

Stage 3

Elderly men with lower income will be our optional customer group.



Problem Solution Target Market Strategy

Financial

Persona: Lim is a banker occasionally suffering from impotency and looking for proper help.



Characteristics

- Smoking habit
- Has one daughter while planning to have a son
- Previously sexually active every week
- · Has friends working as urology doctor
- Working almost everyday, including at home or in office
- Travel for business frequently (avg. 4 times per month)

Name: Lim

Age: **46**

Occupation:

Director in bank

Annual Income:

US\$200K

Pain Points

- ED occurs unregularly (avg. 30% in terms of frequency)
- Not sure if it is caused by psychological or physical problem
- Has consulted doctor (friend) privately but do not have time for further test
- Reluctant to discuss with wife and let her down


Value Proposition

- ✓ Save time with home-based device and short-time test
- ✓ Prompt conclusion with data connection back to hospital
- ✓ Positive communication with his
 - wife based on available ED
 - solution

Go-to Market Strategy(1/3): We propose to focus on medical centers and regional hospitals in Taipei region first, and then expand our business in Central and Kao-pin regions.

1. Aggregated in Three Regions


In Taiwan, the largest three medical resources clusters are *Taipei*, *Central*, and *Kao-pin* regions. It would be easy to focus on those three regions to maximize the cost-efficiency.



2. Start with Taipei

in order to keep lean and minimize initial start-up capital.

Geographic Share of Medical Expenditure



Taipei has 7 medical centers, 20% of Urology doctors and takes up 36% of medical expenditure.



Go-to-Market Strategy (2/3): based on our market insights generated from the medical professions in Taiwan, we will conduct Quadro 2 Strategies to enter Taipei region.

Two Key Opinion Leaders

MD. PU and MD. Huang are the most influential leaders among Urology doctors in Taipei.



YEONG-SHIAU PU, Chairman of TUA Professor of NTUH



William J. Huang, Chairman of TAA Chief Physician of Andrology Division

Two
Core Medical Centers

The most famous urologic medical centers in Taiwan.



National Taiwan University Hospital (NTUH)



Taipei Veterans General Hospital (VGHTPE) Two Medical Associations

in order to include the device for diagnosis in the **treatment guideline**.

- 1. Taiwan Urological Association (TUA)
- Taiwanese Association of Andrology (TAA)



Two
Medical Conferences

- International Section of Annual Urology Conference
- 2. Annual Andrology Conference





Problem Solution Target Market St

Strategy

Financial

Go-to-Market Strategy (3/3): Five years implementation plan is made based on economic level and medical resource concentration level.


	Year 1	Year 2	Year 3	Year 4	Year 5
Market Segment	Medical Center	Medical Center	Medical Center	Medical CentreRegional Hospital	Medical CentreRegional Hospital
Cluster	Taipei	Taipei	Taipei, Central	Taipei, Central, Kao-pin	Taipei, Central, Kao-pin
Quantity	2 medical centers	5 medical centers	10 medical center	11 medical center 12 regional hospital	13 medical center 24 regional hospital
Total Market Share	0.27%	0.87%	1.99%	5.10%	8.66%
Total Revenue	\$87,437	\$288,367	\$670,140	\$1,753,799	\$3,035,767

LARKS

Problem Solution Target Market Str

Strategy Financial

Business & Revenue Model: Based on recycling model, revenue will be charged by one-time usage and long-term rental fee.





15

Financial Projection: Expected breakeven time is 2.68 years with 52% profit rate after tax.

	Year 0	Year 1	Year 2	Year 3	Year 4	Year 5
Total Revenue		\$87,437	\$288,367	\$670,140	\$1,753,799	\$3,035,767
Total Cost		\$113,705	\$186,180	\$307,314	\$695,375	\$1,072,997
EBIT		\$(26,268)	\$102,186	\$362,827	\$1058,424	\$1,962,770
Present Value (20% discount rate)		\$(21,890)	\$56,770	\$167,975	\$408,343	\$631,035
Accumulative NPV	\$(150,000)	\$(171,890)	\$(115,120)	\$52,855	\$461,198	\$1,092,233

Optimistic Scenario

Breakeven time: **2.01** years

Revenue in year 5: US\$ 3,455,042

Profit Margin in year 5: **54%**

Realistic Scenario

Breakeven time: **2.68** years

Revenue in year 5: US\$ 3,035,767

Profit Margin in year 5: **52%**

Not as expected

Breakeven time: **3.10** years

Revenue in year 5: US\$ 2,961,313

Profit Margin in year 5: 50%



Problem Solution Target Market Strategy

Financial

Risk Mitigation

Risk & Challenges Impact Mitigation Constantly seek to work with platforms that have high credibility Technology – Breach of **Personal Data** HIGH Take note of offline breach of data though contracts and company policies. Instead of competing, establish Competitors – Many (big) companies enter partnerships **MEDIUM** the playing field Focus on the service portion that our product seeks to provide. Continuous checks to ensure production Economics of Scale – Problems with scaling quality is maintained **LOW** Establish close contact with suppliers to facilities leading to production delays ensure sufficient components Keep track of any changes to Taiwan's Market Entry – Obstacles entering market medical devices policies. **MEDIUM** due to **medical testing requirements.** Perform due diligence and ensure that all necessary tests are done in advance.



